The Pathology Research Shared Resource (PRC) provides histological and related tissue-based services across the enterprise to Mayo Clinic Cancer Center (MCCC) members at Mayo Clinic in Rochester, MN (MCR), at Mayo Clinic in Arizona (MCA), and at Mayo Clinic in Florida (MCF). PRC works with site based resources to standardize practices across the enterprise. The services include preparation of histology slides for microscopy, tissue microarray construction, immunostaining, digital image capture and analysis, and preparation of tissues for subsequent nucleic acid or protein extraction. A team of cytotechnologists assist with morphologic interpretation of slides, choosing slides and blocks for tissue microarrays, and analysis of microscopic images. PRC provides these services to research and clinical investigators at an affordable cost with reasonable turnaround times. The majority of the services are performed using clinical diagnostic tissues that are formalin fixed and paraffin embedded, allowing MCCC members to take advantage of the wealth of clinical materials for biomarker discovery and validation. PRC also performs services on fresh tissues, animal tissues, and tissue-cultured cells to facilitate translation of basic biology to clinical relevance. PRC functions within a College of American Pathologists (CAP)-accredited quality system to provide consistent services performed according to laboratory standard operating procedures. The services provided by PRC have been vital to MCCC research at Mayo Clinic, providing members with state of the art services that would be difficult to maintain in the laboratories of individual investigators. In addition, many investigators who use PRC are epidemiologists and bioinformaticians in the MCCC Genetic Epidemiology & Risk Assessment Program (GERA), who may not have laboratory space of their own.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113594
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications